rain metastases represent the most common intracranial tumors. 8, 23 Surgical intervention is often recommended for patients with large, symptomatic lesions or for patients who require a pathologic diagnosis. Postoperative whole-brain radiation therapy (WBRT) has been shown to improve local control and distant brain failure, but not overall survival (OS). 13, 20 Given concerns of neurocognitive sequelae following WBRT, 4,6 postoperative stereotactic radiosurgery (SRS) followed by close surveillance has emerged as an alternative treatment paradigm.
For intact brain metastases, a planning target volume (PTV) margin can be added to account for setup uncertainties related to patient immobilization, choice of image-guided radiotherapy, and delivery approach (e.g., linear accelerator [LINAC]-based SRS vs Gamma Knife radiosurgery). 12 In addition to these factors, resection cavities are associated with unique challenges that make target delineation more difficult: irregular size, changes in shape over time, and artifacts due to blood products. 1, 21 These factors lead to higher rates of interobserver bias. While local control rates can be high (75%-80%), Choi et al. retrospectively demonstrated that adding no margin for SRS to resection cavities is associated with worse local control when compared with a 2.0-mm margin. 7 As such, multiple institutions have implemented an additional margin for resection cavities treated with postoperative SRS alone. 16, 28 Adding a margin to ensure adequate target coverage, however, is not without consequence. Larger margins result in an increased dose delivered to adjacent normal brain tissue. Since the volume of brain receiving 10 and 12 Gy correlates with intracranial necrosis for unresected lesions, 2, 17 increasing the PTV margin could result in a higher risk of radiation necrosis. Choi et al., however, demonstrated no toxicity differences between a PTV margin of 2.0 mm and no PTV margin. 7 It therefore remains to be seen how smaller margins (between 0 and 2.0 mm) compare with regard to local control and radiation necrosis. Highlighting this variability, 2 recent prospective studies used varying PTV margins for resection cavities treated with postoperative SRS: the MD Anderson group using a 1.0-mm PTV margin 15 and the Alliance group (study number NC107c) using a 2.0-mm PTV margin. 5 With limited research to date dedicated to investigating the safety and efficacy of different PTV margin size, we retrospectively investigated the treatment outcomes of a margin size of 1.0 mm versus > 1.0 mm for patients who underwent resection of their brain metastases and received postoperative SRS.
Methods

Patients
After obtaining IRB approval, we retrospectively reviewed records of patients who were 18 years or older and underwent craniotomy for brain metastases, followed by postoperative SRS from 2006 to 2016. The IRB determined that individual patient consent was not required for this chart review. Patients were ineligible for this study if they had received prior WBRT or had a diagnosis of a radiosensitive tumor (e.g., small cell lung cancer, lymphoma, and germ cell).
All patients' charts were reviewed for the following characteristics: age at diagnosis, sex, primary tumor histology, preoperative tumor volume on MRI, number of brain metastases, time to surgery, extent of resection classified as gross-total resection (GTR) or subtotal resection (STR), Karnofsky Performance Scale score, Eastern Cooperative Group (ECOG) Performance Status, graded prognostic assessment, and recursive partitioning analysis. The following radiation treatment variables were collected: number of fractions, single fraction-equivalent dose (SFED), technique (framed vs frameless), prescription isodose line (IDL), gross tumor volume (GTV, in cm 3 ), PTV size (cm 3 ), PTV margin (mm), and conformity index. The conformity index was defined as the ratio of the treatment volume and PTV.
Patients were stratified based on PTV margin size. Treated resection cavities were divided into 2 groups: one group with a margin size of 1.0 mm and the other with a margin size > 1.0 mm. For lesions in the > 1.0-mm group, the PTV margin ranged from 1.5 to 3.0 mm, based on physician preference.
Radiation Treatment
Approximately 2-4 weeks after craniotomy, patients underwent CT simulation with a thermoplastic head mask for immobilization (frameless technique) or a rigid head frame (framed technique). A high-resolution CT simulation brain scan was obtained using a SOMATOM Definition AS CT scanner (Siemens Healthineers) with a slice thickness of 0.6 mm. This CT data set was then coregistered with the diagnostic contrast-enhanced MR image (T1-weighted, magnetization-prepared rapid gradientecho sequences) with a slice thickness of 1.0 mm. The diagnostic MR image was obtained within 1-2 weeks of CT simulation and was used for treatment planning. After accurate rigid image registration, the target volume was contoured on the CT scan with the aid of the MR images.
The GTV was defined as the postoperative resection cavity and area of residual disease in cases of STR; the clinical target volume was identical to the GTV. The clinical target volume was then uniformly expanded to form the PTV, with the margin size chosen by the treating physician. The radiation dose and fractionation were also left to the judgment of the treating physician. Historically, our institution has used single-fraction SRS, with the dose based on results from the Radiation Therapy Oncology Group (RTOG) 90-05, 27 but for larger lesions, our clinical practice is to use multifraction radiosurgery to limit toxicity. 9, 14 To account for differences in fractionation, SFED was calculated for each patient using an a/b ratio of 10.
Patients were exclusively treated with LINAC-based SRS within 1 week of CT simulation. All patients were treated using 6-MV photons. Varian Novalis TX (Varian Medical Systems, Inc.) was used to deliver the radiosurgery treatments with a high-definition multileaf collimator thickness of 2.5 mm. If the patient was treated using a rigid, stereotactic head frame, this was placed at the time of CT simulation by a neurosurgeon, followed by treatment delivery a few hours later.
Follow-Up
Post-SRS follow-up consisted of clinical examination and brain MRI 4-6 weeks later, with subsequent follow-up every 3 months thereafter, unless clinically indicated otherwise. Local recurrence was defined as recurrence seen within the prior 80% IDL of the resection cavity on followup MRI. Regional recurrence was defined as the presence of new enhancing lesions distinctly outside the irradiated field. Leptomeningeal disease was defined as new, abnormal leptomeningeal enhancement outside the prior treated region.
Radiographic radiation necrosis was defined as the development of a contrast-enhancing mass within prior radiation treatment fields. 22 Cases were discussed at a multidisciplinary neurooncology tumor board, consisting of neurosurgeons, radiation oncologists, neuroradiologists, medical oncologists, and pathologists, to develop a consensus decision differentiating radiation necrosis versus local recurrence. Additional imaging studies (MR perfusion, MR spectroscopy, and brain PET scans) were obtained when a consensus was not reached. Symptomatic radiation necrosis was defined as development of radiation necrosis requiring treatment; steroids were initially used, with resection reserved for nonresponders. In cases of surgery, patients were deemed to have radiation necrosis if there was no evidence of residual disease; otherwise, they were considered to have local recurrence.
Statistical Analysis
Statistical analysis was divided into lesion-level analysis and patient-level analysis. Local recurrence was evaluated at the lesion level, while radiation necrosis and symptomatic radiation necrosis were evaluated at the patient level. Outcome events (local recurrence, regional recurrence, and symptomatic radiation necrosis) were calculated as time from SRS to date of event. OS was defined as death due to any cause, and patients were censored at time of last follow-up.
Fine and Gray's method was used for multivariate analysis (MVA) of competing risk end points. The Kaplan-Meier method was used to estimate OS, and the log-rank test was used to assess for differences between treatment groups. The Cox proportional hazards model was used to perform MVA to generate hazard ratios with associated 95% confidence intervals. Univariate and multivariate analyses were performed using collected clinical and dosimetric factors to determine their impact on local recurrence, regional recurrence, OS, and symptomatic radiation necrosis. Variables found to be significant on univariate analysis, using a backward selection with an a-level of removal of 0.20, were then entered into MVA. All statistical analyses were performed using SAS (version 9.4, SAS Institute Inc.).
Results
Patient and Lesion Characteristics
Between 2006 and 2016, a total of 133 consecutive patients with 139 resected brain metastases received postoperative SRS at our institution. Table 1 details the patientand lesion-level characteristics.
There were 36 (27.1%) patients in the 1.0-mm margin group and 97 (72.9%) patients in the > 1.0-mm margin group (mean margin size 1.9 mm, median margin size 2.0 mm). Patient characteristics were well balanced, except the 1.0-mm cohort had better ECOG Performance Status (ECOG grade 0: 36.1% vs 19.6%, p = 0.032) and more patients were treated with the framed technique (91.7% vs 66.0%, p = 0.003). The most common histology was nonsmall cell lung cancer (33.3% and 48.5% in the 1.0-mm and > 1.0-mm groups, respectively). There was no statistically significant difference between the tumor types between the groups. Figure 1 illustrates the cumulative incidence of local recurrence stratified by margin size. The 1-year local recurrence rates were 15.2% and 14.3% for the 1.0-mm and > 1.0-mm groups, respectively (p = 0.91). Significant predictors for local recurrence on univariate analysis were ECOG score of 1 (HR 0.26, 95% CI 0.10-0.64; p = 0.004), GTV > 15 cm 3 (HR 4.01, 95% CI 1.67-9.64; p = 0.002), and PTV > 14 cm 3 (HR 4.90, 95% CI 1.12-21.41; p = 0.035). The median time to regional recurrence was 7 months. There was no statistically significant difference for time to development of regional recurrence between the groups (p = 0.572). As depicted in Supplementary Fig. 2 , at 1 year, the probability of regional recurrence in the 1.0-mm margin group was 41.5% versus 49.4% for the > 1.0-mm margin group (p = 0.3603). At 1 year, 17 of 133 patients (actuarial rate of 12.8%) developed recurrence within the leptomeningeal compartment.
Locoregional Recurrence
Symptomatic Radiation Necrosis
Overall, 28 of 133 patients (21.1%) developed symptomatic radiation necrosis, of whom 24 patients were in the > 1-mm group. Using patient-level analysis, at 1 year, 16.7% of patients developed symptomatic radiation necrosis. These patients were initially treated with oral glucocorticoids. Due to refractory symptoms, 3 patients who developed symptomatic radiation necrosis required surgical management whereby pathology confirmed the diagnosis. Of note, these 3 patients all were treated with a margin size > 1.0 mm (median 1.5 mm). One-and 2-year symptomatic radiation necrosis rates (Fig. 2) were 6.0% and 9.1%, and 20.9% and 26.6% in the 1.0-mm and > 1.0-mm margin cohorts, respectively (p = 0.028). Table 3 shows MVA for symptomatic radionecrosis. MVA confirmed that margin size > 1.0 mm (HR 3.07, 95% CI 1.13-8.34; p = 0.028) was a statistically significant predictor for increased rates of symptomatic radiation necrosis. Furthermore, number of fractions > 1 also emerged as a protective factor for symptomatic radiation necrosis (HR 0.13, 95% CI 0.02-0.76; p = 0.023) on MVA. SRS technique (framed vs frameless) and SFED were not found to be statistically significant factors for symptomatic radiation necrosis (p = 0.145).
Overall Survival
The median OS for all patients was 15.6 months. On 
Discussion
To our knowledge, this is the first published study to evaluate the impact of a 1.0-mm PTV margin versus a larger margin size on local recurrence and intracranial toxicity in patients with resected brain metastases. Our investigation shows that expanding the PTV margin beyond 1.0 mm does not improve local recurrence, but is associated with a statistically significant higher rate of symptomatic radiation necrosis compared with a 1.0-mm margin.
In 2011, Choi et al. 7 prospectively compared outcomes of postoperative SRS patients who were treated with a 2.0-mm target margin compared with a 0-mm margin. They found that adding a margin around the resection cavity leads to improved local control without increasing toxicity. Our 1-year local recurrence rate for all lesions was 14.3%, which is higher than the 1-year local recurrence rate reported by Choi et al. 7 of 9.5%. Unlike Choi et al., we used a 1.0-mm margin for the reference patient group. In addition, the median GTV size for our cavities was 11.3 cm 3 , which is 30% larger than the median GTV size of 8.5 cm 3 reported by Choi et al. 7 Using spherical target geom-
, the median cavity size in our study, 11.3 cm 3 , converts to a median maximum cavity diameter of 2.8 cm. When comparing our overall local recurrence rates to those of other studies, Brennan et al. 3 reported a 22% 1-year local recurrence rate with a median maximum cavity diameter of 2.8 cm. Rao et al. 25 published in abstract form a 1-year local recurrence rate of 28%, with cavity dimensions reported as percentages: < 2.6 cm, 33%; 2.6-3.5 cm, 42%; and > 3.5 cm, 25%. Next, Soltys et al. reported a 1-year local recurrence rate of 21% after SRS to a median cavity size of 9.8 cm 3 . 28 Thus, despite a larger median cavity size of 11.3 cm 3 (or median cavity diameter of 2.8 cm), our 1-year rate of local recurrence appears to be lower when compared with prior reported studies.
Our investigation also shows that cavity size larger than 15 cm 3 is a statistically significant predictor for increased rates of local recurrence on MVA, which is a potential reason for why the local recurrence is higher in our study than in that of Choi et al. 7 The observation that larger cavity size is associated with local recurrence is congruent with the finding by Minniti et al., where lesion size larger than 3.0 cm was found to be a statistically significant predictor for increased local recurrence in patients with resected melanoma brain metastases. 18 To compare our results, a 15-cm 3 cavity volume, using spherical geometry, translates to an equivalent lesion diameter of 3.06 cm, which is very similar to the lesion size of 3.0 cm reported by Minniti et al. While Minniti et al. 18 only included brain metastases patients with melanoma histology, Rao et al., 25 in a prospective randomized study of resected brain metastases comparing postoperative SRS to observation, found that preoperative tumor size larger than 3.0 cm was associated with higher rates of local recurrence. Collectively, our finding of worse local recurrence with increas- ing target size is in alignment with that of prior reported studies.
Of the 133 resected brain metastases patients, 16.7% suffered symptomatic radionecrosis at 1 year. Statistically significantly higher 1-and 2-year symptomatic radionecrosis rates were seen in the > 1.0-mm margin cohort than in the 1.0-mm cohort (20.9% and 26.6% vs 6.0% and 9.1%, p = 0.028). Furthermore, all symptomatic patients who required salvage resection were treated with a margin > 1.0 mm (median 1.5 mm). Our overall symptomatic radionecrosis findings are comparable to those of Brennan et al., 3 who reported a radionecrosis rate of 17.5% in 49 patients treated with postoperative radiosurgery. In contrast, Choi et al. 7 noted 1-year toxicity rates of only 8%. Our rate of 16.7% is higher than the report by Choi et al. due to a few underlying factors. First, in our study, radionecrosis was diagnosed radiographically and hence could account for higher reported rates of toxicity. Second, target size is a known predictor for toxicity with intracranial SRS. Our median cavity size was 11.3 cm 3 , whereas the median cavity size as reported by Choi et al. 7 was 8.5 cm 3 . Finally, in our study the median SFED was higher in the > 1.0-mm cohort than in the 1.0-mm cohort (17.5 vs 15 Gy), as was reported by Choi et al. (17.5 vs 16 Gy) . Nonetheless, SFED was not significant on MVA for symptomatic radionecrosis.
In support of our findings, Raore et al. 26 examined resected margin tissue after GTR of a small group of metastatic lesions from a variety of primary sources. Microscopic assessment of the tissue samples showed no tumor cells infiltrating the surrounding brain tissue. This suggested the need to target only a narrow depth of the resection cavity margin (1.0-2.0 mm) to minimize normal tissue injury and prevent adverse effects from SRS. With regard to other factors that persisted on MVA for symptomatic radionecrosis, number of fractions > 1 was found to be a statistically significant protective variable. This finding is consistent with multiple prior reported studies that support the use of hypofractionated SRS for large brain metastases to mitigate the associated toxicity of radionecrosis. [9] [10] [11] 19 We acknowledge a few pertinent limitations of our study. Radionecrosis was determined radiographically, which could lead to higher apparent rates of toxicity when compared with other studies. All of our patients were treated with LINAC-based SRS, and hence it might make it difficult to extrapolate to Gamma Knife radiosurgery. In addition, dosimetric variables (e.g., V10Gy, V12Gy, V15Gy) were not included in the analysis. Finally, similar to other published studies, we have evaluated multiple histologies, which makes it harder to generalize survival results.
Conclusions
This study demonstrates that increasing the PTV margin beyond 1.0 mm for SRS to resected brain metastases results in no improvement in local control but leads to statistically significant increased rates of symptomatic radionecrosis. Furthermore, in congruence with other published studies, cavity size > 3.0 cm is associated with higher rates of local recurrence. 
